Browse News
Filter News
Found 772,049 articles
-
The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.
-
Bristol Myers Squibb’s Reblozyl induced nearly twice the red blood cell transfusion independence compared with the current standard treatment epoetin alfa for lower-risk myelodysplastic syndrome.
-
The New York–based biotech will present data from a Phase I trial of 98 patients showing that fianlimab combined with Libtayo led to an overall response rate of 61% in advanced melanoma.
-
The United States and Belgium Partner to Accelerate the Fight Against Cancer
5/26/2023
SpectronRx will open its first European facility on SCK CEN’s premises
-
Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting
5/26/2023
Genexine announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy for HNSCC in the ASCO.
-
Japan Association for Cellular Agriculture convenes key stakeholders for “Made in Japan” or “Wagyu-like” cultivated meat, in response to Japan PM Kishida’s intention to promote the industry
5/26/2023
Japan Association for Cellular Agriculture, a Japan-based non-profit research institute hosted the inaugural meeting in Tokyo, in response to Japanese Prime Minister Fumio Kishida’s announcement in February 2023 of the intention to develop the domestic cultivated food industry.
-
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference
5/26/2023
Ascentage Pharma announced that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology Annual Meeting.
-
Castellum, Inc. Announces $6 million Cost Reduction Plan
5/26/2023
Castellum, Inc. announces that it is undertaking a cost reduction effort targeting at least $6 million per year in cash and non-cash indirect costs, general and administrative costs, and overhead costs.
-
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023
5/26/2023
Antengene Corporation Limited announced that the latest results from the Phase I/II TORCH-2 study will be presented as a poster at the 2023 American Society for Clinical Oncology Annual Meeting taking place from June 2nd to 6th, 2023 at the McCormick Place Convention Center in Chicago, IL.
-
Masimo Board of Directors Files Definitive Proxy and Issues Letter to Stockholders
5/26/2023
The Masimo Corporation Board of Directors issued a letter to stockholders in connection with its definitive proxy materials filed on May 24, 2023, and the Company’s Annual Meeting of Stockholders to be held on June 26, 2023.
-
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2023
Day One Biopharmaceuticals announced the publication of three abstracts on the American Society of Clinical Oncology website.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 26, 2023
5/26/2023
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that, on May 25, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a newly hired employee.
-
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
5/26/2023
Biophytis SA announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation in France with the French National Authority for Health for the use of Sarconeos [1] in the treatment of adult patients with a severe form of COVID-19, who are at risk of developing a critical form of the disease and for whom therapeutic alternatives are not appropriate.
-
Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
5/26/2023
Invitae, a leading medical genetics company, announced that Chief Financial Officer Yafei Wen is resigning to pursue other opportunities, effective June 30, 2023.
-
Occlutech Q1 2023 - Growth Momentum with Increased Sales and Marketing Activities
5/26/2023
Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.
-
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
5/26/2023
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of Veklury® in COVID-19 patients with severe renal impairment, including those on dialysis.
-
Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2023
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology annual meeting to be held in Chicago, IL.
-
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
5/26/2023
RELIEF THERAPEUTICS Holding SA announced the Annual General Meeting of shareholders will take place Tues., June 20, 2023 at 9 a.m. CEST at avenue de Sécheron 15 in Geneva, near the Relief Therapeutics offices.
-
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
5/26/2023
Innate Pharma SA announced that the abstract entitled “A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia” was published on the ASCO 2023 Annual Meeting website.
-
TScan Therapeutics Announces Pricing of $140 Million Public Offering
5/26/2023
TScan Therapeutics, Inc. announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant.